4-Amino-3-Chlorophenol Hydrochloridis CAS 52671-64-4 Lenvatinib Mesylate puritate media >98.0% (HPLC)

Description:

Nomen: 4-Amino-3-chlorophenolum hydrochloridum

CAS: 52671-64-4

Puritas: >98.0% (HPLC)

Aspectus: Brown solidus pulveris

Medium de Lenvatinib Mesylate CAS 857890-39-2

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum 4-Amino-3-Chlorophenolum Hydrochloridum
Synonyma 2-Chloro-4-Hydroxyaninum Hydrochloridum
CAS Number 618-89-3
CATTUS Number RF-PI1969
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C6H6ClNO·HCl
M. Pondus 180.03
Liquescens punctum 254.0~ 256.0'(decl.)(lit.)
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Firmus Pulvis Brown
Puritas / Analysis Methodus >98.0% (HPLC)
Puritas / Analysis Methodus 97.5~ 102.5% (Titration by AgNO3)
Damnum in Siccatio <0.50%
Residere in Ignition <0.30%
Totalis immunditias <2.00%
Infrared Imaginis Conformat ut Structure
Proton NMR Spectrum Conformat ut Structure
Test Standard Enterprise Standard
Consuetudinem Medium de Mesylate Lenvatinib (CAS: 857890-39-2)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

1

FAQ:

Applicatio:

4-Amino-3-chlorophenolum hydrochloridum (CAS: 52671-64-4) medium est Mesylate Lenvatinib (CAS: 857890-39-2).Lenvatinib (nomen Lenvima artis) medicamentum anti-cancri est pro curatione quarundam generis cancri thyroideae, et in potentia ad alias carcinomata.Lenvatinib adhibetur pro curatione cancri thyroideae differentiatae, quae vel localiter recurrens ormetastaticum, progressivum est, nec curationi cum iodi radioactivo (radioiodine) respondet. LENVATINIB medicina est quae scuta in cellis cancri sistit et cellas cancer accrescens sistit.Adhibetur ut cancer thyroideum et renum cancrum tractare.Compare kinase inhibitores.Lenvatinib inhibitor scuti multi-VEGFR2 et VEGFR3 cum IC50 4 nM et 5.2 nM, respective.

Epistulam tuam hic scribe et mitte nobis